<DOC>
	<DOCNO>NCT02394106</DOCNO>
	<brief_summary>Double-blind , two-parallel-arm , placebo-controlled randomized clinical trial test superiority Ofatumumab versus placebo treatment child DR-INS . Participants stratify accord eGFR enrollment . Eligible participant enter 3-months run-in period , instruction urine collection dipstick reading carefully review , compliance assess immunosuppressive therapy withdraw accord follow scheme : - prednisone taper 0.3 mg/kg per week complete withdrawal ; - calcineurin inhibitor mofetile mycophenolate decrease 50 % withdrawn 2 additional week In order minimize risk complication uncontrolled INS treatment ACE-inhibitor 6 mg/m2 maintain started patient . After run-in period , child randomize intervention arm ( Ofatumumab ) comparator arm ( placebo ) . Randomization stratify eGFR randomization : ≥90 &lt; 90 ml/min/1.73 m2 . All patient follow 12 month leave study time relapse . Relapse define uPCR ≥2000 mg/g ( ≥200 mg/mmol ) ≥ 3+ protein urine dipstick 3 consecutive day .</brief_summary>
	<brief_title>Ofatumumab Children With Drug Resistant Idiopathic Nephrotic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Drug resistance : signifies lack antiproteinuric effect double therapy base steroid plus CNI mofetil mycophenolate ( MMF ) . Steroid resistance define failure achieve complete remission 6 week prednisone 60 mg/m2 . CNI ( cyclosporine/tacrolimus ) resistance define failure achieve complete remission within 6 month plasma concentration cyclosporine ( start dosage 4 mg/kg/day ) tacrolimus ( start dosage 0,1 mg/kg/day ) reach effective plasma concentration . Mofetil Mycophenolate resistance define failure achieve complete remission least 6 month treatment 1200mg/mq/day . Parents'/guardian 's write informed consent , child 's assent give studyrelated procedure part subject 's normal medical care , understand consent may withdraw subject time without prejudice future medical care . Age 2 18 year Histological pattern minimal change disease , mesangial proliferation IgM deposit focal segmental glomerulosclerosis Positivity autoimmunity test ( ANA , dsDNA , ANCA ) . Reduction C3 level . eGFR &lt; 30 ml/min/1.73 m2 valuate accord revise Bedside Schwartz Formula patient 2 17 year CKDEPI Creatinine 2009 Equation 18 year old patient . Hystological pattern characterize element suggestive congenital disease : diffuse mesangial sclerosis without IgM deposit , cysticlike tubular dilatation , mitochondrial abnormality evident electron microscopy , IF suggestive congenital collagen 4 disease . Histological pattern suitable INS pediatric age ( membranous glomerulonephritis , lupus nephritis , diffuse and/or localize vasculitis , amyloidosis ) Homozygous heterozygous mutation podocitary gene , commonly involved etiology INS ( NPHS1 , NPHS2 , NPHS3 , NPHS6 , WT1 , COQ2 , COQ6 , MYO1E , SMARCAL1 , LAMB2 , SCARB2 , CD2AP , TRPC6 , ACTN4 , INF2 , LMX1B , MYH9 ) Pregnancy Neoplasm Infections : Previous actual HBV ( HBeAb positivity ) HCV</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>